Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sensorion Secures ANSM Approval To Launch Phase I/II HearConnex Trial Of SENS-601 In France

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

France

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

Sensorion received approval from the French National Agency for Medicines and Health Products Safety (ANSM) to initiate a Phase I/II clinical trial for their drug SENS-601 targeting hearing loss.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech startup targeting hearing disorders now faces a competitive timeline acceleration in France as ANSM approval opens a new clinical trial opportunity for SENS-601; this may reshape investor and partnership interest in local auditory drug development.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialregulatory-approvalhearing-lossbiotechfrance